Diabetes
The research focuses on the use of new technologies to improve outcomes for people with diabetes. We undertake randomised controlled trials to evaluate the efficacy and safety of automated insulin delivery systems for people with type 1 diabetes, type 2 diabetes and cystic fibrosis related diabetes in the outpatient setting.
Studies currently open to recruitment
COYOTE
The COYOTE study aims to find out if using an automated insulin delivery system (also called a closed-loop system) can improve glucose levels in people with type 2 diabetes compared with standard insulin injections and a glucose sensor.
REACTIVATE
The REACTIVATE study (Phase 2) aims to find out if using an automated insulin system (also called a closed-loop system) can help people with type 2 diabetes achieve remission of their diabetes compared with standard diabetes medications and a glucose sensor.
SENSE
SAVA Technologies are developing 2 new wearable biosensors which will be used to calculate the blood glucose (sugar) levels in people with type 1 or type 2 diabetes who use insulin.
STRIDE
Paused to recruitment until mid 2025
A 12-month, randomized, single-blind, placebo-controlled exposure- response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE)
Find More
Study Location
Diabetes
Currently Recruiting Studies
Previous Studies